180 Life Sciences Corp Stock Price, News & Analysis

180 Life Sciences (NASDAQ: ATNF) has successfully closed a private offering of $156 million in senior secured convertible notes due 2028 to an institutional investor. The notes will begin accruing 4% annual interest after six months and are convertible into common stock at $3.445 per share, subject to potential downward adjustment after nine months.

This offering follows the company's recent $425 million private placement. The proceeds will primarily be used to expand the company's Ethereum (ETH) holdings as part of its treasury strategy. The notes include provisions for company-mandated conversion after six months, subject to certain restrictions.

Clear Street LLC served as financial advisor and exclusive placement agent, with The Loev Law Firm, PC and Reed Smith LLP acting as legal advisors.

180 Life Sciences (NASDAQ: ATNF) has successfully closed a $425 million private placement to implement its Ethereum treasury strategy. The PIPE transaction, priced at $2.65 per share, was led by Electric Capital and Harbour Island, with participation from prominent crypto investors including Borderless Capital and Polychain Capital.

The company plans to use the proceeds primarily to purchase Ethereum (ETH) and implement a yield generation program managed by Electric Capital. The program aims to outperform traditional ETH staking through a combination of staking, lending, and liquidity provisioning. Additionally, the company announced significant governance updates, including the appointment of McAndrew Rudisill as Board Chairman and new independent directors.

The company may further raise up to $150 million through fixed income securities following the PIPE completion.

180 Life Sciences (NASDAQ: ATNF) has announced a significant strategic pivot with a $425 million private placement to establish an Ethereum treasury reserve. The company plans to rebrand as ETHZilla Corporation and will primarily use the proceeds to purchase Ether (ETH). The PIPE transaction, expected to close around August 1, 2025, involves over 60 institutional and crypto-native investors.

Electric Capital will serve as the external asset manager, implementing an on-chain yield generation program designed to outperform traditional ETH staking. The company also plans to launch with Etherealize as a key partner and establish a DeFi Council comprising ecosystem leaders to guide treasury management. Additionally, the company has approval to sell up to $150 million in debt securities following the PIPE closing.

180 Life Sciences Corp. (NASDAQ:ATNF), a biotechnology company transitioning to the iGaming sector, has announced significant enhancements to its legacy intellectual property portfolio through two new patent developments.

The first development is the granting of U.S. Patent No. 12,325,744 B2 by the USPTO, focused on methods for preventing post-operative cognitive decline. This patent, owned by The Kennedy Trust and licensed to 180, covers treatments for reducing cognitive impairment following planned inflammatory triggers like surgery or chemotherapy.

The second development involves a Notice of Allowance from the Canadian Intellectual Property Office for a patent application covering the treatment of localized fibrotic disorders using an IL-33 antagonist. This patent, owned solely by 180, specifically targets conditions like Dupuytren's Disease and Frozen Shoulder.

180 Life Sciences Corp. (NASDAQ:ATNF) has received a Notice of Allowance from the USPTO for a patent application covering a novel method to prevent Post-Operative Cognitive Dysfunction (POCD). The patent focuses on reducing POCD by administering anti-Human tumor necrosis factor (TNF) Alpha monoclonal antibody during surgical procedures.

POCD is a significant complication affecting elderly patients undergoing surgery, manifesting as memory loss, concentration impairment, delirium, and other cognitive issues. The company's method targets inflammatory pathways via ATNF therapy to minimize neuroinflammation post-surgery.

Notably, while this patent strengthens the company's legacy biotechnology portfolio, 180 Life Sciences is currently transitioning its focus to the global iGaming sector, developing online casino and entertainment businesses through its Technology Gaming Platform.

180 Life Sciences has announced a significant share repurchase agreement with Elray Resources and Luxor Capital. The company will acquire and cancel 1,318,000 shares (23.1% of outstanding shares) for $1 million through a structured payment plan: $350,000 directly to Elray and $650,000 to Luxor from future capital raises by April 2026.

The deal includes a Voting Agreement requiring Elray to vote remaining shares according to the Board's recommendations until April 2026, with CEO Blair Jordan holding irrevocable proxy. The agreement features mutual releases, confidentiality obligations, and indemnity protection.

This strategic move aims to reduce dilution and simplify the company's capital structure while preserving cash liquidity. The company plans to focus on monetizing its Technology Gaming Platform through potential online casino acquisitions.

180 Life Sciences Corp. (NASDAQ:ATNF), a biotech company transitioning to international entertainment and iGaming, has announced a $2.9 million registered direct offering and concurrent private placement. The company will sell 1,200,000 common stock shares at $2.41 per share, along with unregistered warrants for an additional 1,200,000 shares. The warrants, exercisable immediately at $2.28 per share, will expire after five and a half years. Maxim Group is serving as the sole placement agent, with the offering expected to close around December 30, 2024.

180 Life Sciences Corp has announced its return to full compliance with Nasdaq Listing Rule 5605(c)(2) following the appointment of Stephen Shoemaker as an independent director and audit committee member. This appointment resolves all previously announced deficiencies in Nasdaq's continued listing requirements.

Interim CEO Blair Jordan confirmed that the company is now focusing on its strategic pivot into the iGaming sector, highlighting the potential of their recently acquired Technology Gaming Platform, particularly in relation to cryptocurrency adoption. The management team and board are aligned on leveraging emerging technologies and market trends in the iGaming industry.

180 Life Sciences Corp (NASDAQ:ATNF) has appointed Stephen Shoemaker to its Board of Directors, effective December 3, 2024. The company, which is transitioning from biotechnology to focus on international entertainment and iGaming, gains Shoemaker's extensive experience in gaming and eSports sectors. As a senior executive, Shoemaker has raised over $2 billion in capital across four companies and has significant experience in scaling high-growth organizations.

At WIN Group, as CEO, Shoemaker led the launch of a licensed iGaming platform that tripled total bet volume in its second month. He also served as CEO of Engine Media Holdings, where he created the first publicly-traded pure-play eSports company. Concurrent with Shoemaker's appointment, Omar Jimenez is stepping down from the Board to focus on his CFO role.